# Oral ONC201 in Adult Recurrent Glioblastoma

> **NCT02525692** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 84 (actual)

## Conditions studied

- Glioblastoma
- Diffuse Midline Glioma
- H3 K27M Glioma
- Thalamic Glioma
- Infratentorial Glioma
- Basal Ganglia Glioma

## Interventions

- **DRUG:** Dordaviprone (ONC201)

## Key facts

- **NCT ID:** NCT02525692
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2023-04-17
- **Final completion:** 2023-04-17
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525692, "Oral ONC201 in Adult Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02525692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*